File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B

TitleRole of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B
Authors
KeywordsAntiviral therapy
Chronic hepatitis B
Core protein allosteric modulator
Functional cure
Hepatitis B core antigen
Issue Date2020
PublisherSpringer Healthcare Communications Ltd. The Journal's web site is located at http://link.springer.com/journal/11901
Citation
Current Hepatology Reports, 2020, Epub 2020-06-22 How to Cite?
AbstractPurpose of Review: Functional cure of chronic hepatitis B (CHB), defined as sustained hepatitis B surface antigen (HBsAg) seroclearance, is associated with favourable clinical outcomes. Nonetheless, the functional cure is rarely achievable by current treatment modalities. Core/capsid inhibitors (core protein allosteric modulators, CpAMs) are a novel drug class that targets the hepatitis B core protein and may have a potential impact on the functional cure. This article reviews the preclinical and clinical results of CpAMs. Recent Findings: CpAMs interfere with the hepatitis B virus (HBV) nucleocapsid assembly and also exert a secondary action on covalently closed circular DNA replenishment. CpAMs are able to sustainably suppress hepatitis B viral load and viral antigens in in vivo studies. In phase I/II clinical trials, CpAMs are well tolerated and are efficacious in suppressing viral replication. CpAMs also have synergistic antiviral effects when combined with nucleoside analogues or pegylated interferon. The clinical data has yet to demonstrate the capability of CpAMs in inducing HBsAg seroclearance, possibly due to the short follow-up period of current studies. There is emerging data showing initial viral antigen reduction with the continuation of CpAMs for more than 24 weeks. Summary: CpAMs have shown promising preclinical and phase I/II clinical data. Data from long-term phase III trials and from combination therapies with other antiviral agents are keenly anticipated.
Persistent Identifierhttp://hdl.handle.net/10722/283730
ISSN

 

DC FieldValueLanguage
dc.contributor.authorHui, RWH-
dc.contributor.authorMak, LY-
dc.contributor.authorSeto, WK-
dc.contributor.authorYuen, MF-
dc.date.accessioned2020-07-03T08:23:17Z-
dc.date.available2020-07-03T08:23:17Z-
dc.date.issued2020-
dc.identifier.citationCurrent Hepatology Reports, 2020, Epub 2020-06-22-
dc.identifier.issn2195-9595-
dc.identifier.urihttp://hdl.handle.net/10722/283730-
dc.description.abstractPurpose of Review: Functional cure of chronic hepatitis B (CHB), defined as sustained hepatitis B surface antigen (HBsAg) seroclearance, is associated with favourable clinical outcomes. Nonetheless, the functional cure is rarely achievable by current treatment modalities. Core/capsid inhibitors (core protein allosteric modulators, CpAMs) are a novel drug class that targets the hepatitis B core protein and may have a potential impact on the functional cure. This article reviews the preclinical and clinical results of CpAMs. Recent Findings: CpAMs interfere with the hepatitis B virus (HBV) nucleocapsid assembly and also exert a secondary action on covalently closed circular DNA replenishment. CpAMs are able to sustainably suppress hepatitis B viral load and viral antigens in in vivo studies. In phase I/II clinical trials, CpAMs are well tolerated and are efficacious in suppressing viral replication. CpAMs also have synergistic antiviral effects when combined with nucleoside analogues or pegylated interferon. The clinical data has yet to demonstrate the capability of CpAMs in inducing HBsAg seroclearance, possibly due to the short follow-up period of current studies. There is emerging data showing initial viral antigen reduction with the continuation of CpAMs for more than 24 weeks. Summary: CpAMs have shown promising preclinical and phase I/II clinical data. Data from long-term phase III trials and from combination therapies with other antiviral agents are keenly anticipated.-
dc.languageeng-
dc.publisherSpringer Healthcare Communications Ltd. The Journal's web site is located at http://link.springer.com/journal/11901-
dc.relation.ispartofCurrent Hepatology Reports-
dc.subjectAntiviral therapy-
dc.subjectChronic hepatitis B-
dc.subjectCore protein allosteric modulator-
dc.subjectFunctional cure-
dc.subjectHepatitis B core antigen-
dc.titleRole of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B-
dc.typeArticle-
dc.identifier.emailMak, LY: lungyi@hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityMak, LY=rp02668-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s11901-020-00523-z-
dc.identifier.hkuros310701-
dc.identifier.volumeEpub 2020-06-22-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl2195-9595-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats